Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Hydromethylthionine mesylate by TauRx Pharmaceuticals for Mild Cognitive Impairment: Likelihood of Approval
Hydromethylthionine mesylate is under clinical development by TauRx Pharmaceuticals and currently in Phase III for Mild Cognitive Impairment. According to...
Data Insights
Hydromethylthionine mesylate by TauRx Pharmaceuticals for Alzheimer's Disease: Likelihood of Approval
Hydromethylthionine mesylate is under clinical development by TauRx Pharmaceuticals and currently in Phase III for Alzheimer's Disease. According to GlobalData,...